Article

[Results of nephron-sparing surgery for renal cell carcinoma of more than 4 cm in diameter].

Service d'urologie du GHU Est (Pitié-Tenon), hôpital Pitié-Salpêtrière, AP-HP, faculté de médecine Pierre-et-Marie-Curie, université Paris-VI, 47-83, boulevard de l'Hôpital, 75651 Paris cedex 13, France.
Progrès en Urologie (impact factor: 0.58). 03/2009; 19(2):69-74. DOI:10.1016/j.purol.2008.10.010 pp.69-74
Source: PubMed

ABSTRACT To date, radical nephrectomy (RN) remains the gold standard treatment for renal cell carcinoma (RCC) larger than 4 cm. However, from the early 1990's, improvements in surgical techniques have lead to the development of nephron-sparing surgery (NSS) for small renal tumours of less than 4 cm in diameter. This surgical procedure avoids nephronic waste with an acceptable morbidity and similar oncological outcomes compared to radical surgery. Recent large published series did not show any difference between NSS and RN in terms of oncological safety. Specific and disease-free five-year survival rates (82% to 97.3% and 81% to 97.3%, respectively) have confirmed the safety of NSS. Regarding laparoscopic NSS, the technique is still under evaluation and only mid-term outcomes are available so far. However, these studies are still limited and longer follow-up is needed before any definitive statement can be made. Current guidelines recommend NSS only in case of RCC of less than 4 cm in diameter in elective indications. In daily practice however, surgical teams are pushing back the limit above the threshold of 4 cm. More and more surgeons are either considering anatomical location or technical expected difficulties rather than just the tumour size. NSS leads to higher risk of bleeding, especially in case of tumours larger than 4 cm. Therefore, it is absolutely necessary to investigate thoroughly the vascularization of the tumour to avoid such complications with exhaustive and accurate preoperative imaging.

0 0
 · 
0 Bookmarks
 · 
32 Views

Keywords

acceptable morbidity
 
anatomical location
 
Current guidelines
 
definitive statement
 
disease-free five-year survival rates
 
elective indications
 
gold standard treatment
 
laparoscopic NSS
 
mid-term outcomes
 
nephron-sparing surgery
 
radical nephrectomy
 
radical surgery
 
renal cell carcinoma
 
similar oncological outcomes
 
small renal tumours
 
surgical procedure avoids nephronic waste
 
surgical teams
 
surgical techniques
 
tumour size
 
tumours larger